Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Three-pronged COCN-Ciba deal

The deal between CoCensys and Ciba has three main elements: the co-development of Acea 1021; the building of a COCN sales force to co-promote four Ciba drugs; and the exercise by COCN of its option to acquire Acea Pharmaceuticals Inc.

Acea 1021 is a glycine antagonist. Blocking glycine in turn blocks the release of glutamate, which opens calcium channels and ultimately causes the death of neurons

Read the full 659 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE